ResMed Inc. (RMD) Insider James Hollingshead Sells 600 Shares

Share on StockTwits

ResMed Inc. (NYSE:RMD) insider James Hollingshead sold 600 shares of the stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $112.09, for a total transaction of $67,254.00. Following the sale, the insider now directly owns 83,689 shares of the company’s stock, valued at approximately $9,380,700.01. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

James Hollingshead also recently made the following trade(s):

  • On Tuesday, November 27th, James Hollingshead sold 5,893 shares of ResMed stock. The shares were sold at an average price of $105.52, for a total transaction of $621,829.36.
  • On Thursday, November 1st, James Hollingshead sold 600 shares of ResMed stock. The shares were sold at an average price of $105.93, for a total transaction of $63,558.00.
  • On Monday, October 1st, James Hollingshead sold 600 shares of ResMed stock. The shares were sold at an average price of $115.88, for a total transaction of $69,528.00.

Shares of NYSE:RMD traded down $1.22 on Thursday, hitting $110.91. The company had a trading volume of 63,993 shares, compared to its average volume of 798,597. ResMed Inc. has a 1 year low of $83.60 and a 1 year high of $116.64. The company has a current ratio of 2.58, a quick ratio of 1.91 and a debt-to-equity ratio of 0.27. The stock has a market cap of $15.98 billion, a price-to-earnings ratio of 31.40, a P/E/G ratio of 2.86 and a beta of 1.01.

ResMed (NYSE:RMD) last posted its earnings results on Thursday, October 25th. The medical equipment provider reported $0.81 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.80 by $0.01. ResMed had a net margin of 13.94% and a return on equity of 26.29%. The firm had revenue of $588.28 million during the quarter, compared to analysts’ expectations of $576.66 million. Equities analysts forecast that ResMed Inc. will post 3.7 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 13th. Stockholders of record on Thursday, November 8th will be given a $0.37 dividend. The ex-dividend date is Wednesday, November 7th. This represents a $1.48 annualized dividend and a dividend yield of 1.33%. ResMed’s dividend payout ratio is 41.93%.

Large investors have recently bought and sold shares of the company. Harvest Fund Management Co. Ltd lifted its position in shares of ResMed by 245.4% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 905 shares of the medical equipment provider’s stock worth $104,000 after purchasing an additional 643 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its position in shares of ResMed by 144.7% in the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,018 shares of the medical equipment provider’s stock worth $117,000 after purchasing an additional 602 shares during the period. Qube Research & Technologies Ltd purchased a new stake in shares of ResMed in the 2nd quarter worth about $148,000. Cerebellum GP LLC purchased a new stake in shares of ResMed in the 3rd quarter worth about $186,000. Finally, Piedmont Investment Advisors LLC purchased a new stake in shares of ResMed in the 2nd quarter worth about $167,000. 65.02% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts have weighed in on the stock. BMO Capital Markets increased their price target on shares of ResMed from $107.00 to $109.00 and gave the company a “market perform” rating in a research report on Friday, October 26th. Credit Suisse Group raised shares of ResMed from a “neutral” rating to an “outperform” rating in a research report on Friday, October 26th. One analyst has rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $114.50.

TRADEMARK VIOLATION NOTICE: “ResMed Inc. (RMD) Insider James Hollingshead Sells 600 Shares” was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.tickerreport.com/banking-finance/3995284/resmed-inc-rmd-insider-james-hollingshead-sells-600-shares.html.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Featured Article: What does EPS mean?

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

ResMed Inc.  Insider James Hollingshead Sells 600 Shares
ResMed Inc. Insider James Hollingshead Sells 600 Shares
NEWTEK Business Services Corp  CEO Barry Sloane Acquires 1,000 Shares
NEWTEK Business Services Corp CEO Barry Sloane Acquires 1,000 Shares
Rexahn Pharmaceuticals  Given a $17.00 Price Target by HC Wainwright Analysts
Rexahn Pharmaceuticals Given a $17.00 Price Target by HC Wainwright Analysts
King Luther Capital Management Corp Buys 37,493 Shares of Union Pacific Co.
King Luther Capital Management Corp Buys 37,493 Shares of Union Pacific Co.
IBC Advanced Alloys  vs. Matthews International  Head-To-Head Analysis
IBC Advanced Alloys vs. Matthews International Head-To-Head Analysis
King Luther Capital Management Corp Sells 500 Shares of Sherwin-Williams Co
King Luther Capital Management Corp Sells 500 Shares of Sherwin-Williams Co


Leave a Reply

© 2006-2018 Ticker Report